{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:10:32Z","timestamp":1792426232767,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"DOI":"10.1186\/s12917-025-05045-8","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T10:21:12Z","timestamp":1763979672000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tumor immune microenvironment and immune phenotypes in PD-L1-tested canine urothelial carcinoma"],"prefix":"10.1186","volume":"21","author":[{"given":"L.V.","family":"Muscatello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"D\u2019Annunzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Tugnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Grillini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Bacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Avallone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Giuliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fiorentino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Volpatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Sarli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"1","key":"5045_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13000-021-01151-x","volume":"16","author":"M Akhtar","year":"2021","unstructured":"Akhtar M, Rashid S, Al-Bozom IA. PD\u2009\u2013\u2009L1 immunostaining: what pathologists need to know. Diagn Pathol. 2021;16(1):1\u201311.","journal-title":"Diagn Pathol"},{"issue":"22","key":"5045_CR2","first-page":"2102","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab versus placebo in Muscle-Invasive. Urothelial Carcinoma. 2021;384(22):2102\u201314.","journal-title":"Urothelial Carcinoma"},{"issue":"1","key":"5045_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fern\u00e1ndez JA, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7(1):1\u20137.","journal-title":"Sci Rep"},{"key":"5045_CR4","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541\u201350. https:\/\/doi.org\/10.1038\/s41591-018-0014-x.","journal-title":"Nat Med"},{"key":"5045_CR5","unstructured":"Bradbury ML, Mullin CM, Gillian SD et al. Clinical outcomes of dogs with transitional cell carcinoma receiving medical therapy, with and without partial cystectomy. Can Vet J. 2021;62(2):133\u201340."},{"key":"5045_CR6","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer\u2013immune set point. Nature. 2017;541:321.","journal-title":"Nature"},{"issue":"7","key":"5045_CR7","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/s41568-023-00578-2","volume":"23","author":"AJ Combes","year":"2023","unstructured":"Combes AJ, Samad B, Krummel MF. Defining and using immune archetypes to classify and treat cancer. Nat Rev Cancer. 2023;23(7):491\u2013505. https:\/\/doi.org\/10.1038\/s41568-023-00578-2.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"5045_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0768-9","volume":"7","author":"AA Davis","year":"2019","unstructured":"Davis AA, Patel VG. The role of PD-L1 expression as a predictive biomarker: an analysis of all US food and drug administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):278. https:\/\/doi.org\/10.1186\/s40425-019-0768-9.","journal-title":"J Immunother Cancer"},{"key":"5045_CR9","doi-asserted-by":"publisher","first-page":"11585","DOI":"10.2147\/CMAR.S274913","volume":"12","author":"R Deng","year":"2020","unstructured":"Deng R, Lu J, Liu X, Peng XH, Wang J, Li XP. PD-L1 expression is highly associated with Tumor-Associated macrophage infiltration in nasopharyngeal carcinoma. Cancer Manag Res. 2020;12:11585\u201396. PMID: 33209062; PMCID: PMC7669506.","journal-title":"Cancer Manag Res"},{"issue":"2","key":"5045_CR10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/his.13946","volume":"76","author":"MR Downes","year":"2020","unstructured":"Downes MR, Slodkowska E, Katabi N, Jungbluth AA, Xu B. Inter- and intraobserver agreement of programmed death ligand 1 scoring in head and neck squamous cell carcinoma, urothelial carcinoma and breast carcinoma. Histopathology. 2020;76(2):191\u2013200. https:\/\/doi.org\/10.1111\/his.13946.","journal-title":"Histopathology"},{"issue":"4","key":"5045_CR11","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/vco.12999","volume":"22","author":"S Eto","year":"2024","unstructured":"Eto S, Kato D, Saeki K, Iguchi T, Shiyu Q, Kamoto S, et al. Comprehensive analysis of the tumour immune microenvironment in canine urothelial carcinoma reveals immunosuppressive mechanisms induced by the COX-prostanoid cascade. Vet Comp Oncol. 2024;22(4):500\u201312. https:\/\/doi.org\/10.1111\/vco.12999.","journal-title":"Vet Comp Oncol"},{"issue":"3","key":"5045_CR12","doi-asserted-by":"publisher","first-page":"703e","DOI":"10.1016\/j.urology.2014.10.020","volume":"85","author":"SF Faraj","year":"2015","unstructured":"Faraj SF, Munari E, Guner G, Taube J, Anders R, Hicks J, Meeker A, Schoenberg M, Bivalacqua T, Drake C, Netto GJ. Assessment of tumoral PD-L1 expression and intratumoral CD8\u2009+\u2009T cells in urothelial carcinoma. Urology. 2015;85(3):703e. 1-6. PMID: 25733301; PMCID: PMC4695997.","journal-title":"Urology"},{"issue":"1","key":"5045_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13046-020-01586-y","volume":"39","author":"F Galli","year":"2020","unstructured":"Galli F, Aguilera JV, Palermo B, Markovic SN, Nistic\u00f2 P, Signore A. Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy. J Exp Clin Cancer Res. 2020;39(1):89. https:\/\/doi.org\/10.1186\/s13046-020-01586-y. PMID: 32423420; PMCID: PMC7236372.","journal-title":"J Exp Clin Cancer Res"},{"issue":"10236","key":"5045_CR14","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","volume":"395","author":"MD Galsky","year":"2020","unstructured":"Galsky MD, Arija J\u00c1A, Bamias A, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10236):1547\u201357.","journal-title":"Lancet"},{"issue":"1","key":"5045_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10120-017-0760-3","volume":"21","author":"K Harada","year":"2018","unstructured":"Harada K, Dong X, Estrella JS, Correa AM, Xu Y, Hofstetter WL, et al. Tumor-associated macrophage infiltration is highly associated with PD-L1 expression in gastric adenocarcinoma. Gastric Cancer. 2018;21(1):31\u201340. https:\/\/doi.org\/10.1007\/s10120-017-0760-3.","journal-title":"Gastric Cancer"},{"key":"5045_CR16","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3389\/fcell.2020.00672","volume":"8","author":"Q Lei","year":"2020","unstructured":"Lei Q, Wang D, Sun K, Wang L, Zhang Y. Resistance mechanisms of anti-PD1\/PDL1 therapy in solid tumors. Front Cell Dev Biol. 2020;8:672. https:\/\/doi.org\/10.3389\/fcell.2020.00672. (PMID: 32793604; PMCID: PMC7385189).","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"5045_CR17","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ccell.2016.10.010","volume":"30","author":"SO Lim","year":"2016","unstructured":"Lim SO, Li CW, Xia W, Cha JH, Chan LC, Wu Y, Chang SS, Lin WC, Hsu JM, Hsu YH, Kim T, Chang WC, Hsu JL, Yamaguchi H, Ding Q, Wang Y, Yang Y, Chen CH, Sahin AA, Yu D, Hortobagyi GN, Hung MC. Deubiquitination and stabilization of PD-L1 by CSN5. Cancer Cell. 2016;30(6):925\u201339. Epub 2016 Nov 17. PMID: 27866850; PMCID: PMC5171205.","journal-title":"Cancer Cell"},{"issue":"6","key":"5045_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0157176","volume":"11","author":"N Maekawa","year":"2016","unstructured":"Maekawa N, Konnai S, Okagawa T, et al. Immunohistochemical analysis of PD-L1 expression in canine malignant cancers and PD-1 expression on lymphocytes in canine oral melanoma. PLoS ONE. 2016;11(6):1\u201313.","journal-title":"PLoS ONE"},{"issue":"1","key":"5045_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41698-020-00139-y","volume":"5","author":"N Maekawa","year":"2021","unstructured":"Maekawa N, Konnai S, Nishimura M, et al. PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma. NPJ Precis Oncol. 2021;5(1):1\u20139.","journal-title":"NPJ Precis Oncol"},{"issue":"24","key":"5045_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers14246188","volume":"14","author":"L Minoli","year":"2022","unstructured":"Minoli L, Licenziato L, Kocikowski M, et al. Development of monoclonal antibodies targeting canine PD-L1 and PD-1 and their clinical relevance in canine apocrine gland anal sac adenocarcinoma. Cancers (Basel). 2022;14(24):1\u201312.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"5045_CR21","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1177\/03009858231209410","volume":"61","author":"LV Muscatello","year":"2024","unstructured":"Muscatello LV, Gobbo F, Avallone G, Innao M, Benazzi C, D\u2019Annunzio G, Romaniello D, Orioles M, Lauriola M, Sarli G. PDL1 immunohistochemistry in canine neoplasms: validation of commercial antibodies, standardization of evaluation, and scoring systems. Vet Pathol. 2024;61(3):393\u2013401.","journal-title":"Vet Pathol"},{"issue":"3","key":"5045_CR22","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/vco.12032","volume":"13","author":"SM Nguyen","year":"2015","unstructured":"Nguyen SM, Thamm DH, Vail DM, London CA. Response evaluation criteria for solid tumours in dogs (v1.0): a veterinary cooperative oncology group (VCOG) consensus document. Vet Comp Oncol. Sep; 2015;13(3):176\u201383.","journal-title":"Vet Comp Oncol"},{"key":"5045_CR23","doi-asserted-by":"publisher","first-page":"5008","DOI":"10.3390\/cancers14205008","volume":"14","author":"CJ Pinard","year":"2022","unstructured":"Pinard CJ, on behalf of the International Immuno-Oncology Biomarker Working Group, Lagree A, Lu F-I, Klein J, Oblak ML, et al. Comparative evaluation of tumor-infiltrating lymphocytes in companion animals: immuno-oncology as a relevant translational model for cancer therapy. Cancers. 2022;14:5008.","journal-title":"Cancers."},{"key":"5045_CR24","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.lungcan.2019.08.023","volume":"136","author":"R Sumitomo","year":"2019","unstructured":"Sumitomo R, Hirai T, Fujita M, Murakami H, Otake Y, Huang CL. PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer. Lung Cancer. 2019;136:136\u201344. Epub 2019 Aug 31. PMID: 31499335.","journal-title":"Lung Cancer"},{"key":"5045_CR25","doi-asserted-by":"publisher","first-page":"640944","DOI":"10.3389\/fvets.2021.640944","volume":"8","author":"M Salvi","year":"2021","unstructured":"Salvi M, Molinari F, Iussich S, Muscatello LV, Pazzini L, Benali S, Banco B, Abramo F, De Maria R, Aresu L. Histopathological classification of canine cutaneous round cell tumors using deep learning: A Multi-Center study. Front Vet Sci. 2021;8:640944. PMID: 33869320; PMCID: PMC8044886.","journal-title":"Front Vet Sci"},{"issue":"10","key":"5045_CR26","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1073\/pnas.0611618104","volume":"104","author":"P Sharma","year":"2007","unstructured":"Sharma P, Shen Y, Wen S, Yamada S, Jungbluth AA, Gnjatic S, et al. CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A. 2007;104(10):3967\u201372. https:\/\/doi.org\/10.1073\/pnas.0611618104.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"5045_CR27","doi-asserted-by":"publisher","first-page":"e008339","DOI":"10.1136\/jitc-2023-008339","volume":"12","author":"J Shen","year":"2024","unstructured":"Shen J, Choi YL, Lee T, Kim H, Chae YK, Dulken BW, Bogdan S, Huang M, Fisher GA, Park S, Lee SH, Hwang JE, Chung JH, Kim L, Song H, Pereira S, Shin S, Lim Y, Ahn CH, Kim S, Oum C, Kim S, Park G, Song S, Jung W, Kim S, Bang YJ, Mok TSK, Ali SM, Ock CY. Inflamed immune phenotype predicts favorable clinical outcomes of immune checkpoint inhibitor therapy across multiple cancer types. J Immunother Cancer. 2024;12(2):e008339. https:\/\/doi.org\/10.1136\/jitc-2023-008339. PMID: 38355279; PMCID: PMC10868175.","journal-title":"J Immunother Cancer"},{"issue":"3","key":"5045_CR28","first-page":"195","volume":"30","author":"K Shosu","year":"2016","unstructured":"Shosu K, Sakurai M, Inoue K, et al. Programmed cell death ligand 1 expression in canine cancer. Vivo. 2016;30(3):195\u2013204.","journal-title":"Vivo"},{"issue":"1","key":"5045_CR29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s12026-025-09624-7","volume":"73","author":"A Singh","year":"2025","unstructured":"Singh A, Raja D, Kaushal S, Seth A, Singh P, Sharma A. Phenotypic characterization of tumor associated macrophages and circulating monocytes in patients with urothelial carcinoma of bladder. Immunol Res. 2025;73(1):66.","journal-title":"Immunol Res"},{"issue":"2","key":"5045_CR30","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","volume":"23","author":"JD Twomey","year":"2021","unstructured":"Twomey JD, Zhang B. Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics. AAPS J. 2021;23(2):39. https:\/\/doi.org\/10.1208\/s12248-021-00574-0. (PMID: 33677681; PMCID: PMC7937597).","journal-title":"AAPS J"},{"issue":"August","key":"5045_CR31","first-page":"1","volume":"14","author":"J van Dorp","year":"2023","unstructured":"van Dorp J, van der Heijden MS. The bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition. Front Immunol. 2023;14(August):1\u201313.","journal-title":"Front Immunol"},{"key":"5045_CR32","doi-asserted-by":"publisher","first-page":"104216","DOI":"10.1016\/j.ebiom.2022.104216","volume":"83","author":"NK Verma","year":"2022","unstructured":"Verma NK, Wong BHS, Poh ZS, Udayakumar A, Verma R, Goh RKJ, Duggan SP, Shelat VG, Chandy KG, Grigoropoulos NF. Obstacles for T-lymphocytes in the tumour microenvironment: therapeutic challenges, advances and opportunities beyond immune checkpoint. EBioMedicine. 2022;83:104216. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104216. Epub 2022 Aug 17. PMID: 35986950; PMCID: PMC9403334.","journal-title":"EBioMedicine"},{"issue":"24","key":"5045_CR33","doi-asserted-by":"publisher","first-page":"20204","DOI":"10.18632\/oncotarget.3887","volume":"6","author":"B Wang","year":"2015","unstructured":"Wang B, Liu H, Dong X, Wu S, Zeng H, Liu Z, Wan D, Dong W, He W, Chen X, Zheng L, Huang J, Lin T. High CD204\u2009+\u2009tumor-infiltrating macrophage density predicts a poor prognosis in patients with urothelial cell carcinoma of the bladder. Oncotarget. 2015;6(24):20204\u201314.","journal-title":"Oncotarget"},{"key":"5045_CR34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2019.01.018","volume":"111","author":"T Yagi","year":"2019","unstructured":"Yagi T, Baba Y, Okadome K, Kiyozumi Y, Hiyoshi Y, Ishimoto T, Iwatsuki M, Miyamoto Y, Yoshida N, Watanabe M, Komohara Y, Baba H. Tumour-associated macrophages are associated with poor prognosis and programmed death ligand 1 expression in oesophageal cancer. Eur J Cancer. 2019;111:38\u201349. Epub 2019 Feb 26. PMID: 30822683.","journal-title":"Eur J Cancer"},{"issue":"1","key":"5045_CR35","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-023-01725-x","volume":"22","author":"H Zhang","year":"2023","unstructured":"Zhang H, Liu L, Liu J, Dang P, Hu S, Yuan W, Sun Z, Liu Y, Wang C. Roles of tumor-associated macrophages in anti-PD-1\/PD-L1 immunotherapy for solid cancers. Mol Cancer. 2023;22(1):58. https:\/\/doi.org\/10.1186\/s12943-023-01725-x. PMID: 36941614; PMCID: PMC10029244.","journal-title":"Mol Cancer"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-025-05045-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12917-025-05045-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-025-05045-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T18:17:56Z","timestamp":1764181076000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-025-05045-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5045"],"URL":"https:\/\/doi.org\/10.1186\/s12917-025-05045-8","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"12 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Histopathology samples were retrieved retrospectively from pathology databases. All previous treatments, including surgery were performed with prior owners\u2019 informed consent, as standard of care in veterinary medicine. As part of the informed consent process, the owners also granted permission for the use of archived samples for research purposes.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"681"}}